Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes

Summary

The study is a 16-week multicenter, randomized, double-blind, placebo-controlled, parallel-designed Phase II clinical study. The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in subjects with diabetic kidney disease in type 2 diabetes.

Timeline

Start

2024-06-21

Primary completion

2025-07-15

Completion

2025-07-25

Publications

• Lv R, Peng L, Xu Y, Du X, Liu H, Wu H, Zhang Y, Li Q, Jiao X, Piao C, Yang S, Lin X, Li L, Ye Z, Chen J; SOLID-DKD Investigator Groupl; SOLID-DKD Investigator Group. Efficacy and safety of HRS-7535, an oral small-molecule GLP-1 receptor agonist, in patients with diabetic kidney disease (SOLID-DKD): a randomised, double-blind, placebo-controlled, phase 2 trial. EClinicalMedicine. 2026 Jul 9;97:104045. doi: 10.1016/j.eclinm.2026.104045. eCollection 2026 Jul.

Drugs

Indications